Prime Healthcare

Founded in 2001, Prime Healthcare has emerged as one of the nation’s leading hospital systems. Prime Healthcare was founded by Dr. Prem Reddy, a physician with a mission to save hospitals, improve community healthcare and provide the very best care to patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

news image

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More

MEDICAL

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

news image

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

news image

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

news image

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More
news image

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More
news image

MEDICAL

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More
news image

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More
news image

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More